Israeli biotech NewStem, founded by Hebrew University of Jerusalem Professor Nissim Benvenisty, has developed a test that verifies if a tumor will be susceptible to chemotherapy.  It prevents a patient having to endure needless treatment with its associated severe adverse side effects.

http://www.timesofisrael.com/israeli-startup-finds-way-to-predict-tumor-resistance-to-chemo/